ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1470

Health-Related Quality of Life in Primary Sjogren’s Syndrome: Insights from Using PROMIS and Comparison to ESSPRI

Dana DiRenzo1, Susan Robinson 2, Clifton Bingham 1 and Thomas Grader-Beck 2, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University, Baltimore

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: quality of life and PROMIS, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Background. Sjogren’s Syndrome (SS) is a chronic, autoimmune disease affecting the exocrine glands that may negatively affect health-related quality of life (HRQL). The importance of measuring symptoms and impacts has increasingly been recognized in patient care and clinical trials. Patient Reported Outcome Measurement Information System (PROMIS) provides universal HRQL instruments, but has not been previously implemented in SS. Currently, EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI) is widely utilized in SS but is limited in measuring HRQL domains. We sought to evaluate how selected PROMIS domains in SS would compare to US normative values and how scores may correlate with the ESSPRI.

Methods: Methods. This was a cross-sectional evaluation of adult patients with SS who completed PROMIS short-forms (SF) (depression 4a, anxiety 4a, fatigue 8a, physical function 10a, pain interference 8a, sleep disturbance 4a, participation in social roles and activities 8a) and had a clinical assessment between May 2018-March 2019. PROMIS T-scores are normalized to a score of 50 with a standard deviation of 10 in the US population; higher scores indicate more of the concept being measured; and a clinically meaningful difference is generally considered ½ SD, or 5 T-score units for some domains. Descriptive statistics, including means and proportions, were calculated for disease-related and sociodemographic variables. Pearson correlation was used to evaluate the relationship between subdomains of the ESSPRI and PROMIS.

Results: Results. Ninety-nine individuals met the 2016 ACR criteria for SS and completed PROMIS SF and clinical measures. Individuals with SS had a median age (IQR) of 57 (43, 66) and were mostly female (90%) and white (81%) (Table 1). Median (IQR) ESSPRI scores were 5.33 (3.66, 7), indicating moderate patient-reported disease activity; median (IQR) ESSRPI subdomain scores were 5 (2, 7) for pain, 6 (5, 8) for dryness, and 6 (4, 7) for fatigue. PROMIS scores for pain interference, fatigue, physical function, and anxiety were at least ½ SD worse than US population normative values. PROMIS pain interference (r=0.78) and fatigue (r=0.79) highly correlated with ESSPRI pain and fatigue sub-domains, respectively. PROMIS fatigue was highly correlated with pain interference (r=0.78) and negatively correlated with social participation (r=-0.71); pain interference was negatively correlated with social participation (r=-0.78) and physical function (r=-0.73) (Table 2). PROMIS anxiety and depression were highly correlated (r=0.80) with each other but not with other ESSPRI or PROMIS domains.

Conclusion: Conclusions. In our SS cohort, PROMIS pain interference and fatigue scores highly correlated with respective ESSPRI domains. Levels of PROMIS pain interference, fatigue, physical function, and anxiety were at least ½ SD worse than US population normative values. Pain interference and fatigue were not highly correlated with anxiety or depression. PROMIS instruments should be considered for use in SS research and clinical care. Future work will require validation in a larger cohort of SS patients and across broader demographics.


Sjogren’s ACR abstract Table 1


Sjogren’s ACR abstract Table 2


Disclosure: D. DiRenzo, None; S. Robinson, None; C. Bingham, Abbvie, 5, AbbVie, 5, BMS, 2, 5, Bristol Meyer Squibb, 2, 5, Bristol Myers-Squibb, 2, 5, Bristol-Myers Squibb, 2, 5, Eli Lilly, 5, Eli/Lilly, 5, Genentech/Roche, 5, Janssen, 5, Janssen Research & Development, LLC, 2, Pfizer Inc, 5, Regeneron/Sanofi, 5, Sanofi/Regeneron, 5; T. Grader-Beck, None.

To cite this abstract in AMA style:

DiRenzo D, Robinson S, Bingham C, Grader-Beck T. Health-Related Quality of Life in Primary Sjogren’s Syndrome: Insights from Using PROMIS and Comparison to ESSPRI [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/health-related-quality-of-life-in-primary-sjogrens-syndrome-insights-from-using-promis-and-comparison-to-esspri/. Accessed April 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-related-quality-of-life-in-primary-sjogrens-syndrome-insights-from-using-promis-and-comparison-to-esspri/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.